NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

This inpatient study is testing a new drug called NBI-1117568 to see if it can safely and effectively reduce acute symptoms in people with schizophrenia who are currently hospitalized during a relapse or flare-up. **You may be eligible if...** - You have a primary diagnosis of schizophrenia - You are currently in the hospital due to worsening symptoms - You are willing to stay in the hospital for the duration of the study and follow the protocol - You are willing to stop taking antipsychotic medications before starting the study drug **You may NOT be eligible if...** - You have a known allergy to NBI-1117568 or its ingredients - You have unstable or serious medical conditions unrelated to schizophrenia - You are considered at imminent risk of harming yourself or others - You have certain other psychiatric or neurological diagnoses Talk to your doctor to see if this trial is right for you.